used donor-derived CD7 CAR-T cells to explore the efficacy and safety in R/R T-ALL, 18/20 patients achieved CR with 7 patients proceeding to HSCT and with a manageable safety profile (67). The gene discussed is CD7; the disease is acute lymphoblastic leukemia.